



Dra. Anniken Burés

Retina and Vitreous Department of the IMO, Institute of Ocular Microsurgery.

Lecturer in the Vitreous and Retina Master's Degree of the Instituto de Microcirugía Ocular. Member of the Ethics Committee of Clinical Research (CEIC) of the IMO

License Number: 37.530

Curriculum

Professional Profile

Ophthalmologist specialising in the retina from the Ocular Microsurgery Institute and associate professor on the Master's Course in Retina and Vitreous run by the IMO and the Faculty of Medicine at the Autonomous University of Barcelona.

Her main area of interest is the uveitis and medical retina. Her research field encompasses inflammatory and infectious diseases of the retina, congenital diseases, acquired and degenerative diseases of the retina, with special attention to age-related macular degeneration (AMD). She is involved in research into pathologies and treatments for medical and surgical retina.

During her medical studies she was awarded a scholarship at the Karolinska Institute in Stockholm, Sweden. She gained proven research experience on the Surgical Doctorate Programme run by the UAB and, in the same year, took part in an Observership at the Medical Retina and Vitreoretinal Surgery Department at Moorfields Eye Hospital in London, United Kingdom.

Training

Bachelor of Medicine and Surgery, University of Barcelona (1996-2002)

Erasmus scholarship at the Karolinska Institutet, Stockholm, Sweden (2000-2001)

Research proficiency in the Doctorate programme in Surgery from the Autonomous University of Barcelona (2007)

Specialisation

Specialist in Ophthalmology, resident at the Hospital Clínic in Barcelona (2003-2007)

Observership at the department of medical retina and vitreoretinal surgery at the Moorfields Eye Hospital, London, United Kingdom (2007)

Professional Appointments

Ophthalmology specialist, with subspecialty in medical and surgical retina at the Hospital Clínic in Barcelona (2007-2010)

Medical and surgical retina research, working in association with Dr Navarro and Dr Mateo at the IMO (2010-2011)

From March 2011, working at the IMO, in the Retina Department, with subspecialty in medical retina and uveitis.

Research

Principal researcher. NEUTON. Phase IV trial to assess the efficacy of aflibercept in naïve patients with macular oedema secondary to central retinal vein occlusion (CRVO) on an individualised treat-and-extend (TAE) treatment regimen. (AFLI -2014-01)

Principal researcher. HARRIER. PHASE III Two-year, randomised, double-blind, multicentre, two-group trial comparing the efficacy and safety of 6 mg RTH258

compared to aflibercept in subjects with wet age-related macular degeneration. (RTH-258-C002)

Principal researcher. AQUA. Open-label Phase-IV study to examine the change of vision-related quality of life in subjects with diabetic macular edema (DME) during treatment with intravitreal injections of 2 mg aflibercept according to EU label for the first year of treatment. (BAY 86-5321 /17850)

Principal researcher. AZURE. An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular degeneration (nAMD). (BAY 86-5321 /16598)

Principal researcher. ATLANTIC. Phase IV, randomised, double-blind trial with simulated control for the analysis of the efficacy, safety and tolerability of aflibercept intravenous monotherapy compared to aflibercept and concomitant photodynamic therapy in patients with polypoidal choroidal vasculopathy. (ECR-AMD-2015-09)

Principal researcher. VIOLET. An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of three different treatment regimens of 2 mg aflibercept administered by intravitreal injections to subjects with diabetic macular edema (DME). (17613)

Collaborating researcher. FOVISTA. Phase III, controlled, randomised, double-blind trial to establish the safety and efficacy of intravitreal administration of Fovista™ (anti-PDGF-B pegylated aptamer) administered in combination with Avastin® or Eylea® compared to Avastin® or Eylea® monotherapy in subjects with subfoveal neovascular age-related macular degeneration. (OPH-1004B)

Collaborating researcher. BIOIMAGE. Phase IV clinical trial to assess the genetic variants of the VEGF pathway as efficacy biomarkers of the treatment with aflibercept in patients with neovascular age-related macular degeneration (AMD). (IMO- AFLI-2013-01)

Collaborating researcher. SPECTRI. Phase III, multicentre, randomised, double-blind, sham-controlled trial to assess the efficacy and safety of lampalizumab administered by intravitreal injection to patients with geographic atrophy secondary to age-related macular degeneration. (GX29185)

IMO
instituto de
microcirugía
ocular

Collaborating researcher. CEDAR. Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration. (150998-005)

Collaborating researcher. IRIS 2. Compensation for blindness with the Intelligent Retinal Implant System (IRIS V2) in patients with retinal dystrophy. (CPP1E_REv2)

Collaborating researcher. A collaborative retrospective trial on the efficacy and safety of intravitreal dexamethasone implant (Ozurdex) I patients with diabetic macular edema (DME). The European DME registrar study (ARTES). (ECR-RET-2014-07)

Collaborating researcher. Identification of new retinal dystrophy genes and characterisation of genotype/phenotype correlations.

Affiliations

Spanish Retina and Vitreous Society, SERV

American Academy of Ophthalmology, AAOO

European Society of Retina Specialists-EURETINA

Societat Catalana d'Oftalmologia-SCOFT

Publications

Mateo C, **Burés-Jelstrup A.** Macular buckling with Ando plombe may increase choroidal thickness and mimic serous retinal detachment seen in the tilted disk syndrome. *Retinal Cases Brief Rep* 2016; 10:327-330

Mazzarella S, Mateo C, Freixes S, **Burés-Jelstrup A.**, Ríos J, Navarro R, García-Arumí J, Corcóstegui B, Arrondo E. Effect of intravitreal injection of dexamethasone 0,7 mg (Ozurdex®) on intraocular pressure in patients with macular edema. *Ophthalmic Res* 2015; 54 (3): 143-9.

Burés-Jelstrup A., Navarro R. *Comprender la Degeneración Macular Asociada a la Edad.* Amat Editorial, Barcelona 2015

García Vilaró M, Vásquez L, Marin A, **Burés-Jelstrup A**, Medel R. *Thermal damage influences endonasal dacryocystorhinostomy success*. *Ophthalmic Res* 2013; 49: 209-2014.

Burés-Jelstrup A, Alkabes M, Gómez-Resca M, Rios J, Corcóstegui B, Mateo C. Visual and anatomical outcome after macular buckling for macular hole with associated foveoschisis in highly myopic eyes. *Br J Ophthalmol* 2013 Oct 29 [Epub ahead of print]

Alkabes M, **Burés-Jelstrup A**, Salinas C, Medeiros MD, Rios J, Corcóstegui B, Mateo C. Macular buckling for previously untreated and recurrent retinal detachment due to high myopic macular hole: a 12-month comparative study. *Graefes Arch Clin Exp Ophthalmol* 2013 Oct 26 [Epub ahead of print]

Mateo C, Dutra Medeiros M, Alkabes M, **Burés-Jelstrup A**, Postorino M, Corcóstegui B. Illuminated Ando Plombe for Optimal Positioning in Highly Myopic Eyes with Vitreoretinal Diseases Secondary to Posterior Staphyloma. *JAMA Ophthalmol* 2013; 131: 1359-1362.

Mateo C, Alkabes M, **Burés-Jelstrup A**. Scleral fixation of dexamethasone intravitreal implant (OZURDEX) in a case of angle-supported lens implantation *Int Ophthalmol* 2013 Aug 9 [Epub ahead of print]

Alkabes M, Padilla L, Salinas C, Nucci P, Vitale L, Pichi F, **Burés-Jelstrup A**, Mateo C. Assessment of OCT measures as prognostic factors in myopic macular hole surgery without foveoschisis. *Graefes Arch Clin Exp Ophthalmol*. 2013; 251: 2521-2527.

Courses and conferences

Burés A. (2016) Speaker. Genetic heterogeneity in retinal dystrophies: challenges in molecular diagnosis. Catalan Association of Retinitis Pigmentosa Sufferers Conference (AARPC). Barcelona

Burés A. (2016) Speaker. Treatment of uveitic macular oedema: discussion and clinical cases. 2nd New Horizons in the Diagnosis and Treatment of Macular Oedema Course. Barcelona

Burés A. (2016) Speaker. Clinical practice: When I use steroids in management of DME... in pseudophakic patients. Enlighten. Allergan. Barcelona

Burés A. (2016) Speaker. Clinical cases "With this, I found ..." Readyt Symposium. Madrid

Burés A. (2016) Speaker. 2nd Interhospital Symposium on Clinical Vitreoretinal Cases. Germans Trias i Pujol Hospital. Badalona

Burés A. (2015) Speaker: 1. Macular oedema in uveitis. 2. Masterclass: Imaging: revolution in diagnosis and monitoring macular diseases. ESASO Retina Academy Conference. Barcelona

Burés A. (2015) Lecturer on the Medical Retina Module at the European School for Advanced Studies in Ophthalmology (ESASO), Università della Svizzera Italiana. Lugano

Burés A. (2015) Speaker. Primary intraocular lymphoma. Course on diabetic retinopathy: Practical aspects. Instituto Barraquer. Barcelona

Burés A. (2015) Speaker. Ocular toxoplasmosis. Course on uveitis at Instituto Oftalmológico Barraquer. Barcelona

Burés A. (2014). Lecturer. *Medical Module: Uveitis*. Medical Retina Course at the European School for Advanced Studies in Ophthalmology (ESASO). Lugano

Burés. A. 2014. Speaker. Medical Retina Module, Lugano.

Burés. A. 2013. Speaker. "*Ocular toxoplasmosis.*" Barraquer Uveitis Course, Barraquer Institute. Barcelona.

Burés. A. 2013. Speaker. "*Birdshot Chorioretinopathy.*" Barraquer Uveitis Course, Barraquer Institute. Barcelona.

Burés. A. 2013. Speaker. "*Staphyloma ridge-associated retinal disturbances.*" Trends in medical & surgical retina. Barcelona.

Burés. A. 2011. Speaker. "*Myopic macular hole.*" Trends in medical & surgical retina. Barcelona.

Burés. A. 2008. Speaker. "*Vitreotomy in toxoplasmic retinochoroiditis.*" Congress of the European Society of Retina (Euretina). Vienna.

Burés. A. 2006. Speaker. "*Oculomotor palsy as initial manifestation of solid tumor.*" Congress of the International Neuroophthalmology Society. Tokyo

Attendance at international courses and conferences

Burés-Jelstrup A. (2011). *Uveitis Course. 11th Euretina Meeting.* Londres.

Burés-Jelstrup A. (2010). *Uveitis Course. 11th Euretina Meeting.* París.

Burés-Jelstrup A. (2007). *Management of intraocular complications during cataract surgery. ESCRS meeting- Stockholm*

Burés-Jelstrup A. (2006). *Decoding the Uveitis Workup: Why, When and What to order.* AAO annual meeting. Las Vegas.